Skip to main content

Day: August 25, 2020

Doré Copper annonce la clôture d’un placement privé d’actions accréditives de 3,1 M$ CA, incluant l’exercice partiel de l’option des placeurs pour compte

NE PAS DISTRIBUER AUX SERVICES DE FIL DE PRESSE DES ÉTATS-UNIS NI DIFFUSER AUX ÉTATS-UNISTORONTO, 25 août 2020 (GLOBE NEWSWIRE) — Doré Copper Mining Corp. (la « Société » ou « Doré Copper ») (TSXV: DCMC) est heureuse d’annoncer qu’elle a procédé à la clôture de son placement privé par l’entremise d’un courtier sur la base des « meilleurs efforts », annoncé précédemment (le « Placement »), aux termes duquel la Société a vendu un total de 2 662 072 actions ordinaires du capital de la Société qui seront admissibles à titre d’ « actions accréditives » au sens du paragraphe 66(15) de la Loi de l’impôt sur le revenu (Canada) et, en ce qui concerne les actions ordinaires émises à des résidents du Québec, de l’article 359.1 de la Loi sur les impôts (Québec) (collectivement, les « Actions accréditives »),...

Continue reading

Allegiant Gold Options Historic Mogollon Silver-Gold District to Summa Silver

VANCOUVER, British Columbia, Aug. 25, 2020 (GLOBE NEWSWIRE) — Allegiant Gold Ltd. (“Allegiant” or the “Company”) (AUAU: TSX-V) (AUXXF: OTCQX) is very pleased to announce that it has signed a definitive agreement with Summa Silver (“Summa”) (CSE: SSVR) whereby Summa can acquire up to a 100% interest in the historic Mogollon silver-gold mining district (the “Property”) of southwestern New Mexico from Allegiant Gold Ltd (“Allegiant”) (TSXV: AUAU).Peter Gianulis, CEO of Allegiant Gold, commented: “We are very excited to have reached an agreement with Summa.  Their dedication and professionalism throughout this process was unparalleled and we are confident that we selected the right partner to develop one of the best undeveloped silver projects in the U.S.  We look forward to their progress and our ability to focus on the development...

Continue reading

Heimavellir hf. – Endurkaup á HEIMA 18.1

Heimavellir hfHeimavellir hafa komist að samkomulagi við Global Macro Absolute Return Advantage Portfolio og Global Macro Portfolio um að Heimavellir hf. kaupi skuldabréfið HEIMA 18.1 af framangreindum sjóðum. Kaupverðið verður greitt með nýju láni og eigið fé. Viðskiptin munu ekki áhrif getu Heimavalla hf. eða dótturfélaga til að standast fjárhagskvaðir annarra skuldabréfa sem Heimavellir hf. eða dótturfélög eru útgefandi að.Búið er að greiða fyrstu greiðsluna og gert er ráð fyrir að viðskiptunum verði lokið fyrir 10. september 2020.Frekari upplýsingar veitir Arnar Gauti Reynisson, framkvæmdastjóris: 860-5300

Continue reading

AQUA BIO TECHNOLOGY ASA: RESOLUTIONS TO INCREASE THE SHARE CAPITAL – FURTHER INFORMATION ABOUT THE SUBSEQUENT OFFERING

Reference is made to the stock exchange notices announced on 18 August 2020 regarding the successful placing of a private placement with gross proceeds of NOK 10.5 million (the “Private Placement“) and a private placement with gross proceeds of NOK 2.13 million (the “Private Placement II“). In order to reduce the dilutive effect of the Private Placement and the Private Placement II, the Board of Directors of Aqua Bio Technology ASA (“ABT” or the “Company“) also decided to initiate a subsequent offering of new shares towards eligible shareholders (the “Subsequent Offering“).The Board of Directors has today resolved share capital increases in connection with the Private Placement II and the Subsequent Offering, as further detailed below.In connection with the Private Placement...

Continue reading

AQUA BIO TECHNOLOGY ASA: VEDTAK OM Å ØKE AKSJEKAPITALEN – NÆRMERE INFORMASJON OM DEN ETTERFØLGENDE EMISJONEN

Det vises til børsmeldingene 18. august 2020 angående vellykket plassering av en rettet emisjon med bruttoproveny på NOK 10,5 millioner (den “Rettede Emisjonen“) og en rettet emisjon med bruttoproveny på NOK 2,13 million (den ” Rettede Emisjonen II“). For å redusere den utvannende effekten av den Rettede Emisjonen og den Rettede Emisjonen II, har Styret i Aqua Bio Technology ASA (“ABT” eller “Selskapet“) også bestemt å iverksette en etterfølgende emisjon overfor kvalifiserte aksjeeiere (den “Etterfølgende Emisjonen“).Styret har i dag vedtatt kapitalforhøyelser i forbindelse med den Rettede Emisjonen II og den Etterfølgende Emisjonen, som nærmere beskrevet nedenfor.I forbindelse med den Rettede Emisjonen II, har Styret vedtatt å øke aksjekapitalen med NOK 1 065 000 ved utstedelse...

Continue reading

Sbanken ASA:

Sbanken ASA has today issued a new Additional Tier 1 bond of NOK 100 million, with a coupon equal to 3 months Nibor + 3.00 percentage points. The Additional Tier 1 bond issue has a perpetual tenor, with a first call option after 5 years.Sbanken ASA has in addition issued NOK 150 million in a new dated Tier 2 bond issue with a coupon equal to 3 months Nibor + 1.25 percentage points. The Tier 2 issue has a tenor of 10 years, with a first call option after 5 years.The two bond issues will sought to be listed on Nordic ABM and the issue dates will be 28 August 2020.Sbanken ASA has in conjunction with the bond issues, with settlement date 28 August 2020, bought back NOK 29 million of ISIN NO0010746456 (SBANK03 PRO) at a price of 100.515 per cent and NOK 16 million of ISIN NO0010746464 (SBANK04 PRO) at a price of 100.271 per cent.Sbanken ASA’s...

Continue reading

Sbanken ASA: Vellykket utstedelse av fondsobligasjon og ansvarlig lån og tilbakekjøp

Sbanken ASA har i dag utstedt et nytt fondsobligasjonslån på NOK 100 millioner, med kupong 3 måneders Nibor + 3,00 prosentpoeng. Fondsobligasjonslånet er evigvarende, med første innløsningsrett etter 5 år.Sbanken ASA har i tillegg utstedt et nytt tidsbegrenset ansvarlig obligasjonslån på NOK 150 millioner, med kupong 3 måneders Nibor + 1,25 prosentpoeng. Det ansvarlige lånet har en løpetid på 10 år med første innløsningsrett etter 5 år.De to obligasjonslånene vil søkes notert på Nordic ABM og emisjonsdato er satt til 28. august 2020.Sbanken ASA har i forbindelse med utstedelsene, med oppgjørsdato 28. august 2020, kjøpt tilbake NOK 29 millioner av ISIN NO0010746456 (SBANK03 PRO) til kurs 100,515 prosent og NOK 16 millioner av ISIN NO0010746464 (SBANK04 PRO) til kurs 100,271 prosent.Styret i Sbanken ASA har godkjent låneopptakene og tilbakekjøpene....

Continue reading

Surna Introduces Expanded Services and Technology Offerings

Announces Full MEP Design Services with Expansion of HVAC TechnologiesBoulder, Colorado, Aug. 25, 2020 (GLOBE NEWSWIRE) — Surna Inc. (OTCQB: SRNA) today announced an expansion of its portfolio of services and products.While Surna has been historically known for its expertise in 2 and 4-pipe chilled water solutions (also known as hydronic cooling and dehumidification), its new technology offerings include:Direct expansion (DX) units with standalone dehumidification options, including split systems, mini-splits and packaged roof top units (RTUs). Complex DX system options with integrated dehumidification via hot gas reheat and wintertime economization. Desiccant solutions for low humidity applications. Racking solutions for optimal airflow designs in tiered layouts.Many clients have already benefited from Surna’s expanded MEP (mechanical,...

Continue reading

Capricor Therapeutics Announces U.S. FDA Acceptance of its IND Application for a Phase 2 Clinical Trial of CAP-1002 in Patients with COVID-19

– The INSPIRE Trial is a Randomized, Placebo-Controlled, Multi-Center Study Evaluating the Safety and Efficacy of Intravenous Infusion of CAP-1002 –– The Study Leverages Capricor’s Lead Asset, CAP-1002 Technology –LOS ANGELES, Aug. 25, 2020 (GLOBE NEWSWIRE) — Capricor Therapeutics (“Capricor”) (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class cell and exosome-based therapeutics for the treatment and prevention of diseases, announced today that the U.S. Food and Drug Administration (FDA) has accepted its investigational new drug (IND) application for a Phase 2 clinical trial of CAP-1002 in patients with COVID-19. The study will enroll patients who have a confirmed diagnosis of SARS-CoV-2 and require supplemental oxygen. Enrollment is expected to commence shortly.The INSPIRE trial...

Continue reading

Veritas Farms, Inc. (OTCQB:VFRM) Reports Financial Results for Quarter and Six Months Ended June 30, 2020

Fort Lauderdale, FL, Aug. 25, 2020 (GLOBE NEWSWIRE) —via NEWMEDIAWIRE — Veritas Farms, Inc. (OTCQB: VFRM) (“Veritas Farms” or the “Company”), a vertically integrated agribusiness focused on the production of full spectrum hemp oil products with naturally occurring cannabinoids, is pleased to announce that the Company has reported its operating results for the quarter and six months ended June 30, 2020, through the filing of its Quarterly Report on Form 10-Q with the SEC. The report, as well as the Company’s other periodic filings with the SEC, may be viewed at www.sec.gov.Selected Financial Highlights – Six Months Ended June 30, 2020, and Quarter Ended June 30, 2020Total Revenue of $3,363,699 in 2020 vs $4,496,275 in 2019Total Revenue of $2,209,388 in Q2-2020 vs $2,971,345 in Q2-2019Tripled e-commerce revenue in Q2 2020 vs...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.